What is the projected market valuation of the Canine Arthritis Treatment Market by 2035?

The projected market valuation for the Canine Arthritis Treatment Market is expected to reach 4.31 USD Billion by 2035. Read More

What was the market valuation of the Canine Arthritis Treatment Market in 2024?

The overall market valuation of the Canine Arthritis Treatment Market was 2.404 USD Billion in 2024. Read More

What is the expected CAGR for the Canine Arthritis Treatment Market during the forecast period 2025 - 2035?

The expected CAGR for the Canine Arthritis Treatment Market during the forecast period 2025 - 2035 is 5.45%. Read More

Which type of arthritis treatment segment is projected to have the highest valuation by 2035?

The Osteoarthritis treatment segment is projected to reach 2.2 USD Billion by 2035, indicating the highest valuation among arthritis types. Read More

What are the leading medication types in the Canine Arthritis Treatment Market?

The leading medication types include Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Disease-Modifying Anti-Rheumatic Drugs (DMARDs), with projected valuations of 1.73 USD Billion and 0.87 USD Billion respectively by 2035. Read More

Which companies are key players in the Canine Arthritis Treatment Market?

Key players in the Canine Arthritis Treatment Market include Zoetis, Boehringer Ingelheim, Elanco Animal Health, and Merck Animal Health. Read More

What is the projected valuation for nutritional supplements in the Canine Arthritis Treatment Market by 2035?

The projected valuation for nutritional supplements in the Canine Arthritis Treatment Market is expected to reach 0.87 USD Billion by 2035. Read More

How does the market for injectable treatments compare to oral treatments in 2035?

By 2035, the market for injectable treatments is projected to reach 1.29 USD Billion, while oral treatments are expected to reach 1.73 USD Billion. Read More

What is the expected market size for canine arthritis treatments targeting cats by 2035?

The expected market size for canine arthritis treatments targeting cats is projected to reach 1.5 USD Billion by 2035. Read More

What trends are influencing the growth of the Canine Arthritis Treatment Market?

Trends influencing growth include increasing awareness of canine arthritis and advancements in treatment options, contributing to a projected market expansion. Read More

Canine Arthritis Treatment Market

ID: MRFR/HC/39364-HCR

128 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Canine Arthritis Treatment Market Research Report By Type of Arthritis (Osteoarthritis, Rheumatoid Arthritis, Other Types), By Medication Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Immunosuppressants, Nutritional Supplements, Pain Relievers), By Mode of Administration (Oral, Injectable, Transdermal, Topical), By Target Patient Type (Dogs, Cats, Other Animals) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Canine Arthritis Treatment Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.45%

2024 Market Size$ 2.4 Billion

2025 Market Size$ 2.54 Billion

2035 Market Size$ 4.31 Billion

Key Players

Zoetis

Boehringer Ingelheim

Elanco Animal Health

Merck Animal Health

Vetoquinol

Ceva Santé Animale

Trends

Rise of Natural Remedies
Technological Advancements in Treatment
Increased Focus on Preventive Care

Opportunities

Aging Dog Population
Growing Pet Ownership
Expansion of Pet Insurance

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type of Arthritis (USD Billion)
  1. 4.1.1 Osteoarthritis
  2. 4.1.2 Rheumatoid Arthritis
  3. 4.1.3 Other Types
2. 4.2 Healthcare, BY Medication Type (USD Billion)
  1. 4.2.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  2. 4.2.2 Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  3. 4.2.3 Immunosuppressants
  4. 4.2.4 Nutritional Supplements
  5. 4.2.5 Pain Relievers
3. 4.3 Healthcare, BY Mode of Administration (USD Billion)
  1. 4.3.1 Oral
  2. 4.3.2 Injectable
  3. 4.3.3 Transdermal
  4. 4.3.4 Topical
4. 4.4 Healthcare, BY Target Patient Type (USD Billion)
  1. 4.4.1 Dogs
  2. 4.4.2 Cats
  3. 4.4.3 Other Animals
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Zoetis (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Elanco Animal Health (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck Animal Health (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Vetoquinol (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Ceva Santé Animale (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 PetIQ (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Dechra Pharmaceuticals (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Virbac (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE OF ARTHRITIS
4. 6.4 US MARKET ANALYSIS BY MEDICATION TYPE
5. 6.5 US MARKET ANALYSIS BY MODE OF ADMINISTRATION
6. 6.6 US MARKET ANALYSIS BY TARGET PATIENT TYPE
7. 6.7 CANADA MARKET ANALYSIS BY TYPE OF ARTHRITIS
8. 6.8 CANADA MARKET ANALYSIS BY MEDICATION TYPE
9. 6.9 CANADA MARKET ANALYSIS BY MODE OF ADMINISTRATION
10. 6.10 CANADA MARKET ANALYSIS BY TARGET PATIENT TYPE
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF ARTHRITIS
13. 6.13 GERMANY MARKET ANALYSIS BY MEDICATION TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY MODE OF ADMINISTRATION
15. 6.15 GERMANY MARKET ANALYSIS BY TARGET PATIENT TYPE
16. 6.16 UK MARKET ANALYSIS BY TYPE OF ARTHRITIS
17. 6.17 UK MARKET ANALYSIS BY MEDICATION TYPE
18. 6.18 UK MARKET ANALYSIS BY MODE OF ADMINISTRATION
19. 6.19 UK MARKET ANALYSIS BY TARGET PATIENT TYPE
20. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF ARTHRITIS
21. 6.21 FRANCE MARKET ANALYSIS BY MEDICATION TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY MODE OF ADMINISTRATION
23. 6.23 FRANCE MARKET ANALYSIS BY TARGET PATIENT TYPE
24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
25. 6.25 RUSSIA MARKET ANALYSIS BY MEDICATION TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY MODE OF ADMINISTRATION
27. 6.27 RUSSIA MARKET ANALYSIS BY TARGET PATIENT TYPE
28. 6.28 ITALY MARKET ANALYSIS BY TYPE OF ARTHRITIS
29. 6.29 ITALY MARKET ANALYSIS BY MEDICATION TYPE
30. 6.30 ITALY MARKET ANALYSIS BY MODE OF ADMINISTRATION
31. 6.31 ITALY MARKET ANALYSIS BY TARGET PATIENT TYPE
32. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF ARTHRITIS
33. 6.33 SPAIN MARKET ANALYSIS BY MEDICATION TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY MODE OF ADMINISTRATION
35. 6.35 SPAIN MARKET ANALYSIS BY TARGET PATIENT TYPE
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF ARTHRITIS
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY MEDICATION TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY MODE OF ADMINISTRATION
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY TARGET PATIENT TYPE
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY TYPE OF ARTHRITIS
42. 6.42 CHINA MARKET ANALYSIS BY MEDICATION TYPE
43. 6.43 CHINA MARKET ANALYSIS BY MODE OF ADMINISTRATION
44. 6.44 CHINA MARKET ANALYSIS BY TARGET PATIENT TYPE
45. 6.45 INDIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
46. 6.46 INDIA MARKET ANALYSIS BY MEDICATION TYPE
47. 6.47 INDIA MARKET ANALYSIS BY MODE OF ADMINISTRATION
48. 6.48 INDIA MARKET ANALYSIS BY TARGET PATIENT TYPE
49. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF ARTHRITIS
50. 6.50 JAPAN MARKET ANALYSIS BY MEDICATION TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY MODE OF ADMINISTRATION
52. 6.52 JAPAN MARKET ANALYSIS BY TARGET PATIENT TYPE
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF ARTHRITIS
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY MEDICATION TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY MODE OF ADMINISTRATION
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY TARGET PATIENT TYPE
57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
58. 6.58 MALAYSIA MARKET ANALYSIS BY MEDICATION TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY MODE OF ADMINISTRATION
60. 6.60 MALAYSIA MARKET ANALYSIS BY TARGET PATIENT TYPE
61. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF ARTHRITIS
62. 6.62 THAILAND MARKET ANALYSIS BY MEDICATION TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY MODE OF ADMINISTRATION
64. 6.64 THAILAND MARKET ANALYSIS BY TARGET PATIENT TYPE
65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
66. 6.66 INDONESIA MARKET ANALYSIS BY MEDICATION TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY MODE OF ADMINISTRATION
68. 6.68 INDONESIA MARKET ANALYSIS BY TARGET PATIENT TYPE
69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF ARTHRITIS
70. 6.70 REST OF APAC MARKET ANALYSIS BY MEDICATION TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY MODE OF ADMINISTRATION
72. 6.72 REST OF APAC MARKET ANALYSIS BY TARGET PATIENT TYPE
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF ARTHRITIS
75. 6.75 BRAZIL MARKET ANALYSIS BY MEDICATION TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY MODE OF ADMINISTRATION
77. 6.77 BRAZIL MARKET ANALYSIS BY TARGET PATIENT TYPE
78. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF ARTHRITIS
79. 6.79 MEXICO MARKET ANALYSIS BY MEDICATION TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY MODE OF ADMINISTRATION
81. 6.81 MEXICO MARKET ANALYSIS BY TARGET PATIENT TYPE
82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF ARTHRITIS
83. 6.83 ARGENTINA MARKET ANALYSIS BY MEDICATION TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY MODE OF ADMINISTRATION
85. 6.85 ARGENTINA MARKET ANALYSIS BY TARGET PATIENT TYPE
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF ARTHRITIS
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY MEDICATION TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY MODE OF ADMINISTRATION
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET PATIENT TYPE
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF ARTHRITIS
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY MEDICATION TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY MODE OF ADMINISTRATION
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TARGET PATIENT TYPE
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF ARTHRITIS
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY MEDICATION TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY MODE OF ADMINISTRATION
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TARGET PATIENT TYPE
99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF ARTHRITIS
100. 6.100 REST OF MEA MARKET ANALYSIS BY MEDICATION TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY MODE OF ADMINISTRATION
102. 6.102 REST OF MEA MARKET ANALYSIS BY TARGET PATIENT TYPE
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY TYPE OF ARTHRITIS, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY TYPE OF ARTHRITIS, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY MEDICATION TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY MEDICATION TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY MODE OF ADMINISTRATION, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY MODE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY TARGET PATIENT TYPE, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY TARGET PATIENT TYPE, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.2.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.3.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.4.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.5.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.6.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.7.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.8.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.9.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.10.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.11.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.12.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.13.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.14.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.15.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.16.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.17.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.18.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.19.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.20.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.21.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.22.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.23.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.24.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.25.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.26.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.27.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.28.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.29.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
  2. 7.30.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Canine Arthritis Treatment Market Segmentation

Canine Arthritis Treatment Market By Type of Arthritis (USD Billion, 2025-2035)

Osteoarthritis
Rheumatoid Arthritis
Other Types

Canine Arthritis Treatment Market By Medication Type (USD Billion, 2025-2035)

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Immunosuppressants
Nutritional Supplements
Pain Relievers

Canine Arthritis Treatment Market By Mode of Administration (USD Billion, 2025-2035)

Oral
Injectable
Transdermal
Topical

Canine Arthritis Treatment Market By Target Patient Type (USD Billion, 2025-2035)

Dogs
Cats
Other Animals

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”